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ABSTRACT
Staphylococcus aureus is a leading cause of bacteraemia. This study analysed temporal trends from 18 702
adult cases of S. aureus bacteraemia in Denmark between 1981 and 2000. After stratiﬁcation for mode of
acquisition, 57% of cases were hospital-acquired (HA), 28% were community-acquired (CA) and 15%
were of undetermined acquisition (UA). Incidence rates increased from 18.2 to 30.5 cases ⁄ 100 000
population. Annual rates increased by 6.4% for CA, by 2.2% for HA and by 3.6% for UA cases,
respectively. Case-mortality associated with HA bacteraemia decreased from 36.2% to 20.7% (43% rate
reduction, p 0.0001), compared with a decrease from 34.5% to 26.5% (23% rate reduction, p 0.0001) for
CA bacteraemia. Following multivariate analysis, age, pneumonia, endocarditis and chronic illness were
associated with increased mortality, regardless of the mode of acquisition. Overall, mortality associated
with S. aureus bacteraemia declined signiﬁcantly between 1981 and 2000, but incidence rates doubled, so
that the total number of deaths increased. These data emphasise the public health importance of
S. aureus bacteraemia and the need for further preventive measures and improved care in order to
reduce incidence rates and improve outcomes.
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INTRODUCTION
Staphylococcus aureus is an important cause of
hospital-acquired (HA) and community-acquired
(CA) morbidity and mortality. Recent studies of
S. aureus bacteraemia have demonstrated high
incidence rates worldwide [1–3], but the epidemi-
ology of HA bacteraemia and that of CA bacter-
aemia differ substantially; for example, HA
bacteraemia is related largely to invasive proce-
dures and devices, whereas CA bacteraemia is
related to host factors and carrier status. Several
predisposing risk-factors for S. aureus infection
have undergone signiﬁcant changes during the
past 20 years; for example, changes in demogra-
phy have shifted the age distribution towards an
elderly population; sedentary lifestyles and obes-
ity have increased rates of diabetes; more ad-
vanced regimens of chemotherapy and other
immunosuppressive treatments are in use; and
intravascular devices and invasive procedures are
now used widely. However, an increased age,
underlying co-morbid disease, and the type and
site of infection, continue to be risk-factors asso-
ciated with an increased risk of death from
bacteraemia [4,5].
Although S. aureus is the most frequent Gram-
positive pathogen isolated from blood, little is
known concerning recent temporal changes in the
incidence and mortality associated with S. aureus
bacteraemia. The present study used the ongoing
nationwide registration of all Danish cases of bac-
teraemic S. aureus infection to analyse temporal
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trends in mortality and incidence of HA and




A continuous, nationwide registration of S. aureus infections in
Denmark has been carried out at the Staphylococcal Laborat-
ory at the Statens Serum Institut, Copenhagen, since 1956 [6].
More than 90% of strains isolated from blood cultures are
referred for typing and antibiotic susceptibility testing. The
present study deﬁned a case as an individual with S. aureus
bacteraemia who was identiﬁed via the Statens Serum Institut
database between 1981 and 2000. All subsequent episodes of
S. aureus bacteraemia occurring in an individual patient within
3 months were regarded as a relapse and were excluded from
the study. Danish resident population data and hospital
admission data were obtained from the Danish National
Bureau of Statistics (Danmarks Statistik; http://www.dst.dk)
and were used to calculate incidence rates nationwide and
among speciﬁed subgroups. The Ethics Committee for Copen-
hagen and Frederiksberg Counties approved the study
(01-369 ⁄ 93).
Data collection
Data were extracted from discharge records annually by a
qualiﬁed clinician. Data extracted included age, gender,
reported chronic illness, source of bacteraemia (hospital,
community or undetermined), and the site of infection asso-
ciated with S. aureus bacteraemia. Chronic illness included
diabetes, chronic liver disease, chronic kidney disease, malig-
nancy, immunosuppression, infection with human immuno-
deﬁciency virus 1, intravenous drug use, chronic skin disease
and collagenoses. A primary focus was deﬁned as a skin
infection, a surgical wound, an intravascular device, a urinary
tract infection, or a respiratory tract infection if stated in the
discharge record; otherwise, the focus was recorded as
unknown. A discharge diagnosis of endocarditis, osteomyeli-
tis ⁄ arthritis or meningitis (recorded from 1990 onwards) was
classiﬁed as a secondary focus. Outcome was registered as
alive or dead at discharge, or unknown.
Antibiotic susceptibility
All isolates were tested at the Statens Serum Institut using
Neosensitabs (Rosco, Taastrup, Denmark) [7].
Statistics
Incidences were normalised to the population distribution and
to hospital admission rates, and were presented with 95% CIs.
Qualitative variables were compared by Fisher’s exact test or
Pearson’s chi-square test. Annual data were divided into four
periods (1981–1985, 1986–1990, 1991–1995 and 1996–2000) for
the assessment of temporal changes.
Multivariate logistic regression was performed to deter-
mine the risk of death after adjusting for possible confounders.
Subjects with unknown vital status were classiﬁed as alive for
analytical purposes. All variables in the multivariate analysis
were analysed using the forced entry procedure. Tests for
interaction among variables were performed by the log
likelihood test after including an interaction term. The good-
ness of ﬁt of the model was tested with the Hosmer–
Lemeshow test [8], which revealed adequate model ﬁt
(p >0.2). All values were two-sided. Analyses were performed
using SPSS v.11.5 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
Table 1 shows the age and gender of all patients
according to the acquisition group. In brief, 57%
of cases were HA, 28% were CA, and 15% were
of undetermined acquisition (UA); 60% of cases
involved male patients in all three acquisition
categories. Patients with CA bacteraemia were
younger than patients with either HA or UA
bacteraemia. A primary focus of either skin or
lung was predominant among CA infections,
whereas surgery, a vascular device or a lung
focus were the predominant primary foci of HA
and UA infections. For all three categories, >50%
had an unknown primary focus; a secondary
focus was detected for 30% of CA bacteraemias,
but for <5% of HA and UA infections. The
Table 1. Characteristics of patients with hospital acquisi-
tion, community acquisition or unknown acquisition of
Staphylococcus aureus bacteraemia
Hospital-acquired






Males, % 60.0 58.6 59.2
Age, years (%)
21–30 4.1 7.3 6.4
31–40 6.5 10.6 9.9
41–50 10.4 9.4 13.3
51–60 15.8 12.2 17.7
61–70 23.8 18.4 22.2
71–80 25.5 24.4 20.9
>80 13.9 17.7 9.7
Primary focus, %
Skin infection 4.1 18.2 6.2
Surgical infection 16.5 0.7 5.9
Vascular device 13.2 1.0 7.8
Dialysis 2.5 0.6 7.0
Urinary tract infection 2.3 0.5 0.6
Pulmonary infection 7.5 17.3 5.2
Other 0.9 0.2 0.1
Unknown 53.0 61.4 67.2
Secondary focus, %
None 94.3 69.1 87.8
Endocarditis 2.0 12.5 5.3
Osteomyelitis ⁄ arthritis 3.5 16.9 6.6
Meningitis 0.1 1.4 0.3
Chronic illness, %
None 48.0 55.0 47.6
1 42.0 38.6 41.2
>1 10.0 6.4 11.2
MRSA, % 0.4 0.2 0.5
MRSA, methicillin-resistant Staphylococcus aureus.
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presence of a chronic illness was slightly more
frequent in patients with HA or UA infections
than in patients with CA infections. Finally,
methicillin-resistant S. aureus (MRSA) bacterae-
mia was infrequent (0.3%), but twice as many
cases were HA or UA infections than were CA
infections.
Incidence rates
The number of patients with S. aureus bacterae-
mia increased from 571 in 1981 to 1172 in 2000 (an
annual increase of 5.3%). After normalisation to
population changes, the incidence of S. aureus
bacteraemia increased 1.7-fold during the 20-year
period, from 18.2 cases ⁄ 100 000 population to
30.5 cases ⁄ 100 000 population, with an annual
increase of 3.4% (Fig. 1a). However, population-
adjusted incidence rates increased less for HA
and UA bacteraemia (annual increase of 2.2% and
3.6%, respectively) than for CA bacteraemia
(6.4% per year) (Fig. 1b). In particular, incidence
rates of CA bacteraemia among males increased
by 7.2% annually during the study period.
Among cases of HA bacteraemia, annual
increases in incidence were <2.9% for each age
group. The largest increase was detected among
individuals aged 21–30 years (2.9% annually) and
individuals aged 51–60 years (2.7% annually).
Among individuals aged >80 years, the annual
rate declined by 1% annually. Annual increases in
incidence rates among cases of CA varied
between 5.0% and 8.8%. The largest annual
increase occurred among the oldest age groups
(61–70 years, 7.1%; >80 years, 8.8%), and among
individuals aged 31–40 years (7.6%).
During the study period, the Danish adult
population (aged >20 years) increased from
3 603 265 in 1981 to 4 027 422 in 2000 (5.9%
average annual increase). Hospital admission
rates were stable throughout the study period
(c. 850 000–900 000 annual adult admissions).
After adjustment for admission rates, the increase
in incidence of S. aureus bacteraemia increased
from 108 ⁄ 100 000 admissions between 1981 and
1985 to 172 ⁄ 100 000 admissions between 1996 and
2000, corresponding to an annual increase of
3.0%.
Mortality
The overall case-mortality rate decreased from
34.5% to 21.7% during the study period (i.e., a
37.1% rate reduction) (Fig. 1a). Despite the im-
proved survival rates, the total number of in-
hospital deaths associated with S. aureus
bacteraemia increased from 1143 in 1981–1985 to
1325 in 1996–2000 (6.3–6.6 deaths ⁄ 100 000 popu-
lation, respectively). Among cases of HA bacter-
aemia, survival rates improved from 63.8% to
79.3% (43% rate reduction) (Table 2). Statistically
signiﬁcant changes occurred in all age groups,
but with considerable variation. In the youngest
age group, case-mortality rates were reduced by
81%, whereas the reduction was 26% in the
oldest age group. Changes in case-mortality rates
among males were greater than among females.
Case-mortality rates were reduced for all groups
of primary foci, but were only statistically signi-
ﬁcant for surgical, vascular device-associated,
pulmonary and other ⁄unknown infections. The
decline in mortality from HA endocarditis was
statistically signiﬁcant, but mortality remained
high throughout the study period. Although an
increase in mortality rates associated with HA
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Fig. 1. (a) In-hospital mortality rate and population-adjus-
ted incidence of Staphylococcus aureus bacteraemia. (b)
Population-adjusted incidence according to acquisition
setting, 1981–2000. All values are annual incidence rates
with 95% CIs.
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second and third study periods, the overall rates
declined and remained low. Rate reductions were
larger among patients with reported chronic
illness, and therefore mortality rates during the
last study period were similar for patients with or
without reported chronic illness. Cases of HA
MRSA were few throughout the study period, but
the associated mortality rate remained above
average.
Among cases of CA bacteraemia, survival rates
improved from 65.5% to 73.5% (23% rate reduc-
tion) (Table 3). Mortality rates declined for all age
groups, but the reductions were only statistically
signiﬁcant in individuals aged 51–80 years. The
largest reduction occurred among individuals
aged 51–60 years. Among individuals with CA
bacteraemia who were aged >80 years, mortality
rates remained unchanged (between 46.1% and
50.0%) throughout the study period. Mortality
rates among males were signiﬁcantly reduced by
28%, and a trend towards a signiﬁcant (15%)
reduction was observed among females. The
dominant primary foci were skin, lung and
unknown infections. Signiﬁcantly reduced mor-
tality rates were observed in each group. Mortal-
ity rates associated with endocarditis declined
signiﬁcantly, whereas mortality rates associated
with osteomyelitis ⁄ arthritis increased signiﬁ-
cantly initially, but then declined and remained
unchanged during the study period. There was a
reduction in mortality rates among individuals
with and without chronic illness. Mortality rates
associated with CA MRSA remained high.
Among cases of UA bacteraemia, survival rates
improved from 73.7% to 84.9% (43% rate reduc-
tion).
Multivariate analysis
Multivariate logistic regression analysis was
used to assess the risk of death in each
acquisition group. Because a signiﬁcant interac-
tion between mode of acquisition and infection
focus was detected, the analysis was stratiﬁed
Table 2. Case-mortality rates among 10 558 cases of hos-
pital-acquired Staphylococcus aureus bacteraemia, 1981–
2000










All 36.2 27.8 23.8 20.7 0.0001
Age, years
21–30 16.9 3.8 8.2 3.2 0.001
31–40 18.0 18.3 10.6 9.4 0.02
41–50 24.7 18.1 12.7 10.2 0.0001
51–60 32.1 27.1 19.9 14.4 0.0001
61–70 38.4 28.8 23.4 18.9 0.0001
71–80 42.5 32.8 27.7 27.7 0.0001
>80 45.3 40.2 43.2 33.5 0.002
Gender
Male 37.5 27.7 22.4 20.2 0.0001
Female 34.3 28.1 25.9 21.5 0.0001
Primary focus
Skin infection 29.1 20.4 32.0 18.6 0.06
Surgical infection 29.4 21.2 19.1 12.7 0.0001
Vascular device 13.2 6.7 9.1 6.6 0.021
Dialysis 14.3 5.9 11.7 9.9 6.1
Urinary tract infection 13.1 5.9 5.3 9.7 0.38
Pulmonary infection 57.6 52.8 48.6 41.6 0.01
Other 38.5 20.7 17.9 0.0 0.04
Unknown 40.7 32.7 27.7 26.9 0.0001
Secondary focus
None 36.2 27.1 23.8 20.7 0.0001
Endocarditis 55.9 61.4 35.3 41.9 0.03
Osteomyelitis ⁄ arthritis 15.8 23.1 19.7 13.9 0.38
Meningitis NA NA 36.4 25.0 0.68
Chronic illness
None 31.2 23.9 22.2 21.2 0.0001
1 41.4 30.2 24.7 20.6 0.0001
>1 42.4 36.3 28.1 19.1 0.0001
MRSA
No 36.2 27.8 23.8 20.7 0.0001
Yes 36.4 33.3 28.6 30.0 0.98
NA, data not available; MRSA, methicillin-resistant Staphylococcus aureus.
Table 3. Case-mortality rates among 5302 cases of com-
munity-acquired Staphylococcus aureus bacteraemia, 1981–
2000










All 34.5 31.7 29.8 26.5 0.0001
Age, years
21–30 7.8 6.0 3.6 2.3 0.29
31–40 14.3 12.6 15.0 6.8 0.08
41–50 28.6 19.2 18.8 17.8 0.30
51–60 33.0 30.3 18.5 19.3 0.005
61–70 42.0 37.1 32.9 27.5 0.007
71–80 41.1 39.6 37.7 30.0 0.01
>80 46.1 49.1 50.0 46.4 0.79
Gender
Male 36.0 29.6 28.5 25.8 0.001
Female 32.5 34.3 31.6 27.5 0.07
Primary focus
Skin infection 20.2 17.6 16.5 10.0 0.008
Surgical infection 0 9.1 28.6 0 0.15
Vascular device 14.3 6.7 31.6 10.0 0.24
Dialysis 25.0 0 0 0 0.17
Urinary tract infection 0 0 0 0 –
Pulmonary infection 50.0 38.0 45.7 44.7 0.16
Other 0 0 0 0 –
Unknown 34.5 35.4 29.2 28.2 0.002
Secondary focus
None 34.5 33.7 33.3 30.9 0.33
Endocarditis 51.6 44.2 27.2 23.9 0.0001
Osteomyelitis ⁄ arthritis 11.6 15.0 14.6 8.3 0.05
Meningitis NA NA 58.8 52.0 0.57
Chronic illness
None 30.8 32.2 31.4 29.8 0.75
1 40.3 30.5 29.2 21.2 0.0001
>1 31.6 35.3 19.6 26.5 0.13
MRSA
No 34.4 31.8 29.7 26.5 0.0001
Yes 100 0 66.7 33.3 0.31
NA, data not available; MRSA, methicillin-resistant Staphylococcus aureus.
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by mode of acquisition. For each acquisition
group, increasing age, a diagnosis of pulmonary
infection, endocarditis and the presence of co-
morbidity were associated independently with
an increased risk of death; a diagnosis of
osteomyelitis ⁄ arthritis was associated with a
decreased risk of death compared to bacterae-
mia without a secondary focus. Among cases of
HA bacteraemia, a vascular device, dialysis or a
urinary tract infection were associated with a
decreased risk of death. The model variables for
each acquisition group, with associated ORs, are
shown in Table 4.
DISCUSSION
The results of this investigation of 18 702 adult
cases of S. aureus bacteraemia documented a 37%
decrease in mortality during the past 20 years,
while incidence rates during the same period
nearly doubled. Marked differences were ob-
served between cases of HA and CA bacteraemia.
Rates of CA bacteraemia increased the most, and
CA bacteraemia now has the highest overall
mortality rate.
A two-fold increase in the incidence of S. aureus
bacteraemia is consistent with a recent report
from Finland [9] and other reports on all-cause
sepsis [10–13]. Incidence rates changed differen-
tially, depending on the mode of acquisition.
Cases of CA bacteraemia increased at a two- to
three-fold higher rate than did HA infections.
Incidence rates of CA bacteraemia increased more
among the oldest individuals, but this was not the
case for HA bacteraemia, where the changes were
more uniform among age groups. The reasons for
these changes may be multifactorial. Culture
techniques have become more sensitive, but do
not explain a continuing, but differential, increase
in incidence across acquisition and age groups.
Higher culture activity or increased hospital
admission rates are other possible explanations,
but this was not the case in a previous study [14].
Changes in age distribution, leading to a growing
and increasingly frail population of elderly indi-
viduals, may account, in part, for the larger
increase in the incidence of CA compared with
HA cases of bacteraemia. Certainly, older age is a
risk associated with invasive disease [12,15].
Furthermore, a higher proportion of cases was
found to have more than one underlying co-
morbidity, and chronic illness was a strong
predisposing factor for invasive infection [12,15].
Hospital-related procedures and wider use of
immunosuppressive therapy may also have con-
tributed, but the design of the study did not
permit detailed analysis of this and other poten-
tial risk-factors. Further studies are required to
investigate the detailed epidemiology behind the
increase in incidence.
Few studies have provided longitudinal data
concerning mortality rates resulting from S. aure-
us bacteraemia, which were believed to have been
stable for several decades [13,16]. However, mor-
tality rates from all-cause sepsis have declined
moderately during the past decades [13,17]. Inter-
estingly, Martin et al. [13] found that the decline
in mortality rates occurred in sepsis caused by
Gram-negative, but not Gram-positive, organ-
isms. This contrasts with the results of the present
study, and the reason for the discrepancy is not
immediately clear. Differences in study popula-
tions (e.g., age and race), geographical region and
healthcare provision and practice may have con-
tributed. However, an overall mortality rate of
22% is comparable with the results of other recent
studies [3,18–20]. Mortality rates from HA and
Table 4. Multivariate analysis of factors associated with
mortality among cases of hospital- and community-
acquired Staphylococcus aureus bacteraemia, 1981–2000




1986–1990 0.70 (0.61–0.80) 0.96 (0.77–1.19)
1991–1995 0.60 (0.52–0.68) 0.82 (0.67–1.04)
1996–2000 0.48 (0.42–0.54) 0.65 (0.53–0.79)
Age (per 10-year increment) 1.38 (1.34–1.43) 1.55 (1.48–1.61)
Gender
Male 1.0 1.0
Female 1.02 (0.93–1.12) 0.98 (0.86–1.12)
Primary focus
Skin infection 1.0 1.0
Surgical infection 0.89 (0.69–1.15) 0.98 (0.36–2.65)
Vascular device 0.34 (0.26–0.46) 1.14 (0.53–2.45)
Dialysis 0.40 (0.25–0.64) 0.74 (0.22–2.58)
Urinary tract infection 0.26 (0.15–0.42) –
Pulmonary infection 3.22 (2.47–4.21) 4.20 (3.32–5.32)
Other 0.95 (0.55–1.64) –
Unknown 1.53 (1.21–1.92) 2.45 (2.00–3.02)
Secondary focus
None 1.0 1.0
Endocarditis 2.95 (2.19–3.97) 1.58 (1.29–1.92)
Osteomyelitis ⁄ arthritis 0.68 (0.52–0.91) 0.33 (0.26–0.41)
Meningitis 2.24 (0.71–7.05) 3.09 (1.87–5.08)
Chronic illness
None 1.0 1.0
1 1.45 (1.31–1.60) 1.34 (1.16–1.55)
>1 1.76 (1.50–2.07) 1.14 (0.86–1.50)
MRSA
No 1.0 1.0
Yes 1.78 (0.89–3.56) 1.19 (0.25–5.62)
MRSA, methicillin-resistant Staphylococcus aureus.
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CA endocarditis decreased, but remained high. A
recent study of a large number of cases of
S. aureus endocarditis revealed mortality rates of
15–30% [21]. The present study did not permit a
detailed analysis of the discrepancy. Meningitis
and pulmonary infections were also associated
with the highest mortality rates throughout the
study period, which is consistent with previous
reports [12,22]. Mortality rates associated with
dialysis and vascular devices were low through-
out the study period, which is in contrast to the
study of Engemann et al. [23], but in line with the
ﬁndings of Jernigan and Farr [24]. In order to
improve survival rates in cases of endocarditis,
meningitis and pulmonary infections, further
research into pathogenesis, antibiotic and surgical
treatment, as well as prevention, is warranted.
Rates of MRSA infection were low throughout
the study period, probably because of control
policies in Denmark, based on the prompt isola-
tion of MRSA cases [25]. Low MRSA rates are
unique to Denmark, the rest of Scandinavia and
The Netherlands [26,27]. Unfortunately, increas-
ing numbers of cases of MRSA infections are now
being detected in Denmark (DANMAP 2004;
http://www.dfvf.dk/ﬁles/ﬁler/zoonosecentret/
publikationer/Danmap/Danmap_2004.pdf). This
is a major concern, since invasive infections
caused by MRSA are associated with increased
morbidity, mortality and cost [28,29]. Further
studies and initiatives are currently underway to
control the spread of MRSA in Denmark.
The present study has certain limitations. The
study used a prospective registry of a very large
number of S. aureus bacteraemias over a continu-
ous 20-year study period to analyse temporal
trends. The dataset was representative of different
settings, because it included all microbiology
departments in Denmark. However, the use of
discharge records limits the quality of some of the
data; e.g., detailed information concerning diag-
nostic procedures was not available, and thus it
was not always possible to determine the primary
focus of infection or to rule out secondary
infectious complications. Furthermore, a severity
index score to assess the severity of bacteraemia
could not be calculated from the dataset, so that
changes in disease severity over time could be
neither assessed nor analysed. Only cases with
positive blood cultures were studied. Thus, the
true incidence of invasive S. aureus disease was
probably underestimated. However, S. aureus
bacteraemia provides an easily identiﬁable indi-
cator of invasive S. aureus disease incidence.
Finally, although discharge records were exam-
ined carefully to ascertain variables, records were
not always complete, and case patients were not
always interviewed.
In conclusion, this study revealed that mortality
rates associated with S. aureus bacteraemia have
declined signiﬁcantly during the past 20 years.
This may be a result of changes in epidemiology,
as well as better and improved treatments. How-
ever, incidence rates doubled, resulting in an
increase in the total number of deaths. These data
emphasise the public health importance of S. au-
reus bacteraemia and the need for further pre-
ventive measures and improved care in order to
reduce incidence rates and further improve out-
comes. Particular attention should be given to CA
bacteraemia because of the higher overall mortal-
ity rate.
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